Pfizer To Appeal Sutent Patent Revocation; Says Ruling Will Deter Investments And Partnerships
This article was originally published in PharmAsia News
Executive Summary
In the latest twist to a long-drawn saga, Pfizer’s patent on Sutent was revoked based on an opposition filed by Cipla. The decision may trigger wide commercial repercussions.